Humulin R Cartridge (Insulin Human (Rdna))

Humulin R Cartridge is indicated for the treatment of diabetes mellitus where rapid‑acting insulin is required to control blood glucose levels.

• Type 1 diabetes mellitus in adults, adolescents, and children.
• Type 2 diabetes mellitus when basal insulin alone does not achieve target glycaemic control.
• Management of hyperglycaemia during pregnancy (gestational diabetes) under specialist supervision.
• Use in insulin pump therapy or as a bolus dose before meals.
• Hospital or acute care settings for rapid glucose correction.

• Humulin R delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, facilitating translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose concentrations. The rapid onset of action reflects its formulation without protamine, allowing peak activity within 2–4 hours after subcutaneous administration.

Adverse reactions reported with Humulin R Cartridge are generally related to its pharmacologic activity and formulation.

Common

• Hypoglycaemia (low blood glucose) – the most frequent reaction.
• Injection site reactions such as redness, swelling or itching.
• Lipodystrophy, including lipohypertrophy at repeated injection sites.
• Weight gain associated with improved glycaemic control.
• Nausea or abdominal discomfort occasionally reported after injection.

Serious

• Severe hypoglycaemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.
• Persistent hyperglycaemia indicating possible insulin resistance.
• Localized infection at injection site requiring medical attention.

When prescribing or using Humulin R Cartridge, healthcare professionals should consider several precautionary measures to minimise risks and ensure optimal therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose changes, or when sick.
• Educate patients on proper injection technique to avoid lipohypertrophy.
• Review concomitant medications that can mask hypoglycaemia symptoms.
• Advise caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Store the cartridge at controlled temperatures and avoid freezing.
• Do not use if the cartridge shows particulate matter or discoloration.

Humulin R Cartridge may interact with other agents that affect glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• High‑dose beta‑blockers that can mask hypoglycaemia symptoms.
• MAO‑A inhibitors combined with sympathomimetic drugs, increasing risk of severe hypoglycaemia.
• Thiazide diuretics, which may increase blood glucose levels.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which can potentiate hypoglycaemia.
• Corticosteroids, which may raise blood glucose and require insulin dose increase.
• Alcohol consumption, especially in excess, as it can cause delayed hypoglycaemia.
• Beta‑agonist inhalers for asthma, which can raise glucose transiently.